A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 88, Issue 1, 2000, Pages 91-94

  Fedele, Luigi ^a   Bianchi, Stefano ^b   Raffaelli, Ricciarda ^a   Zanconato, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Hormone replacement therapy; Menopause; Tibolone; Uterine myomas

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AMENORRHEA; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; MENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPOTTING; UTERUS MYOMA; UTERUS WEIGHT;

EID: 0033988668     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(99)00115-3     Document Type: Article

References (15)

1. Rein M.S., Barbieri R.L., Friedman A.J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 172:1995;14-18.
2. Brandon D.D., Erickson T.E., Keenan E.J., et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 80:1995;1876-1881.
3. Howe S.R., Gottardis M.M., Everitt J.I., et al. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology. 136:1995;4996-5003.
4. de Visser J., Coert A., Feenstra H., et al. Endocrinological studies on (7α,17α)-17 hydroxy-7-methyl-19-norpropen-5(10)-en-20-yn-3-one (Org OD 14). Arzneimittelforschung. 34:1984;1010-1017.
5. Meuwissen J.H., Wiegerinck M.A., Haverkorn M.J. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas. 21:1995;121-125.
6. Sener A.B., Seckin N.C., Ozmen S., et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril. 65:1996;354-357.
7. Frigo P., Eppel W., Asseryanis E., et al. The effects of hormone sustitution in depot form on the uterus in a group of 50 perimenopausal women - a vaginosonographic study. Maturitas. 21:1995;221-225.
8. Gregoriou O., Vitorias N., Papadias C., et al. Effect of tibolone on postmenopausal women with myomas. Maturitas. 27:1997;187-191.
9. Zalud I., Conway C., Schulman H., et al. Endometrial and myometrial thickness and uterine blood flow in postmenopausal women: the influence of hormonal replacement therapy and age. J Ultrasound Med. 12:1993;737-741.
10. Friedman A.J., Thomas P.P. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol. 85:1995;631-635.
11. Townsend D.E., Fields G., McCausland A., et al. Diagnostic and operative hysteroscopy in the management of persistent postmenopausal bleeding. Obstet Gynecol. 82:1993;419-421.
12. Rymer J., Crook D., Sidhu M., et al. Effects of tibolone on serum concentrations of lipoprotein (a) in postmenopausal women. Acta Endocrinol. 128:1993;259-262.
13. Ginsburg J., Prelevic G., Butler D., et al. Clinical experience with tibolone (Livial) over 8 years. Maturitas. 21:1995;71-76.
14. Milner M.H., Sinnott M.M., Cooke T.M., et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol. 87:1996;593-599.
15. Bjarnason N.H., Bjarnason K., Haarbo J., et al. Tibolone: influence on markers of cardiovascular risk. J Clin Endocrinol Metab. 82:1997;1752-1756.